Exact Mass: 740.3771576

Exact Mass Matches: 740.3771576

Found 91 metabolites which its exact mass value is equals to given mass value 740.3771576, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PA(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(9Z)-hexadec-9-enoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z))

[(2R)-2-[(9Z)-hexadec-9-enoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(6Z,9Z,12Z)/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(18:3(6Z,9Z,12Z)/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(6Z,9Z,12Z)/5-iso PGF2VI), in particular, consists of one chain of one 6Z,9Z,12Z-octadecatrienoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/18:3(6Z,9Z,12Z))

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(5-iso PGF2VI/18:3(6Z,9Z,12Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/18:3(6Z,9Z,12Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 6Z,9Z,12Z-octadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9Z,12Z,15Z)/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(18:3(9Z,12Z,15Z)/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9Z,12Z,15Z)/5-iso PGF2VI), in particular, consists of one chain of one 9Z,12Z,15Z-octadecatrienoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/18:3(9Z,12Z,15Z))

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxy]phosphonic acid

C39H65O11P (740.426427)


PA(5-iso PGF2VI/18:3(9Z,12Z,15Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/18:3(9Z,12Z,15Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 9Z,12Z,15Z-octadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   

cinobufagin 3-pimeloylarginine ester|Cinobufagin-3-pimeloylargininester

cinobufagin 3-pimeloylarginine ester|Cinobufagin-3-pimeloylargininester

C39H56N4O10 (740.3996236)


   
   
   

(25S)-22alpha,25-epoxy-26-[(beta-D-glucopyranosyl)oxy]-3beta-hydroxyfurost-5-en-1-beta-yl alpha-L-arabinopyranoside

(25S)-22alpha,25-epoxy-26-[(beta-D-glucopyranosyl)oxy]-3beta-hydroxyfurost-5-en-1-beta-yl alpha-L-arabinopyranoside

C38H60O14 (740.398286)


   

(25S)-Spirost-5-en-3beta,17alpha,27-triol-3-O-6)>-beta-D-glucopyranoside|(25S)-Spirost-5-en-3beta,17alpha,27-triol-3-O-[alpha-L-arabinopyranosyl(1->6)]-beta-D-glucopyranoside|(25S)-spirostan-5-en-3beta,17alpha,27-triol 3-O-[alpha-L-arabinopyranosyl-(1?6)]-beta-D-glucopyranoside

(25S)-Spirost-5-en-3beta,17alpha,27-triol-3-O-6)>-beta-D-glucopyranoside|(25S)-Spirost-5-en-3beta,17alpha,27-triol-3-O-[alpha-L-arabinopyranosyl(1->6)]-beta-D-glucopyranoside|(25S)-spirostan-5-en-3beta,17alpha,27-triol 3-O-[alpha-L-arabinopyranosyl-(1?6)]-beta-D-glucopyranoside

C38H60O14 (740.398286)


   

(3beta,5beta,16beta)-3-[(6-deoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-galactopyranosyl)oxy]-14,16-dihydroxycard-20(22)-enolide 16-formate|16beta-Formyloxy-3beta-(O4(?)beta-D-glucopyranosyl-O3-methyl-beta-D-fucopyranosyloxy)-14-hydroxy-5beta,14beta-card-20(22)-enolid|16beta-formyloxy-3beta-(O4(?)beta-D-glucopyranosyl-O3-methyl-beta-D-fucopyranosyloxy)-14-hydroxy-5beta,14beta-card-20(22)-enolide

(3beta,5beta,16beta)-3-[(6-deoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-galactopyranosyl)oxy]-14,16-dihydroxycard-20(22)-enolide 16-formate|16beta-Formyloxy-3beta-(O4(?)beta-D-glucopyranosyl-O3-methyl-beta-D-fucopyranosyloxy)-14-hydroxy-5beta,14beta-card-20(22)-enolid|16beta-formyloxy-3beta-(O4(?)beta-D-glucopyranosyl-O3-methyl-beta-D-fucopyranosyloxy)-14-hydroxy-5beta,14beta-card-20(22)-enolide

C37H56O15 (740.3619026)


   
   

19-acetylglucofrugoside

19-acetylglucofrugoside

C37H56O15 (740.3619026)


   

(25R)-2alpha,3beta,17alpha-trihydroxy-spirost-5-en-1beta-yl O-[O-alpha-L-rhamnopyranosyl-(1->2)]-beta-D-xylopyranoside|atropuroside B

(25R)-2alpha,3beta,17alpha-trihydroxy-spirost-5-en-1beta-yl O-[O-alpha-L-rhamnopyranosyl-(1->2)]-beta-D-xylopyranoside|atropuroside B

C38H60O14 (740.398286)


   

(3beta,7alpha,25R)-spirost-5-ene-3,7-diol-3-O-alpha-L-arabinofuranosyl-(1->4)-beta-D-glucopyranoside

(3beta,7alpha,25R)-spirost-5-ene-3,7-diol-3-O-alpha-L-arabinofuranosyl-(1->4)-beta-D-glucopyranoside

C38H60O14 (740.398286)


   

(3beta,17alpha,25S)-spirost-5-ene-3,17,27-triol-3-O-alpha-L-arabinofuranosyl-(1->4)-beta-D-glucopyranoside

(3beta,17alpha,25S)-spirost-5-ene-3,17,27-triol-3-O-alpha-L-arabinofuranosyl-(1->4)-beta-D-glucopyranoside

C38H60O14 (740.398286)


   
   
   

1beta,3beta-dihydroxypregna-5,16-dien-20-one 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-O-[beta-D-xylopyranosyl)-(1]3)]-alpha-L-arabinopyranoside]

1beta,3beta-dihydroxypregna-5,16-dien-20-one 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-O-[beta-D-xylopyranosyl)-(1]3)]-alpha-L-arabinopyranoside]

C37H56O15 (740.3619026)


   

C38H56N6O9_Acetamide, N-[eicosahydro-21-[(4-methoxyphenyl)methyl]-18,22-dimethyl-6-(1-methylethyl)-9-(1-methylpropyl)-5,8,11,16,20,23-hexaoxo-5H,16H-dipyrrolo[2,1-f:2,1-o][1,4,7,10,13,16]oxapentaazacyclononadecin-17-yl]

NCGC00381196-01_C38H56N6O9_Acetamide, N-[eicosahydro-21-[(4-methoxyphenyl)methyl]-18,22-dimethyl-6-(1-methylethyl)-9-(1-methylpropyl)-5,8,11,16,20,23-hexaoxo-5H,16H-dipyrrolo[2,1-f:2,1-o][1,4,7,10,13,16]oxapentaazacyclononadecin-17-yl]-

C38H56N6O9 (740.4108566000001)


   

PKODiA-PI

1-hexadecanoyl-2-(5-oxo-7-carboxy-6E-heptenoyl)-sn-glycero-3-phospho-(1-myo-inositol)

C33H57O16P (740.3384052)


   
   

C6 NBD Sphingomyelin (d18:1/6:0)

C6 NBD Sphingomyelin (d18:1/6:0)

C35H61N6O9P (740.4237426)


   

(3beta,5beta,16beta)-3-((6-Deoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-galactopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide 16-formate

(3beta,5beta,16beta)-3-((6-Deoxy-4-O-beta-D-glucopyranosyl-3-O-methyl-beta-D-galactopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide 16-formate

C37H56O15 (740.3619026)


   

dimethyl-[(1S,10S,12S,13R,21S,23S)-4,8,12-trihydroxy-10-[(2R,3R,4R,5S,6S)-4-hydroxy-3,5-dimethoxy-4,6-dimethyloxan-2-yl]oxy-13-methoxycarbonyl-1,12-dimethyl-6,17-dioxo-25-oxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2,4,7(16),8,14,18-hexaen-23-yl]azanium

dimethyl-[(1S,10S,12S,13R,21S,23S)-4,8,12-trihydroxy-10-[(2R,3R,4R,5S,6S)-4-hydroxy-3,5-dimethoxy-4,6-dimethyloxan-2-yl]oxy-13-methoxycarbonyl-1,12-dimethyl-6,17-dioxo-25-oxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2,4,7(16),8,14,18-hexaen-23-yl]azanium

C39H50NO13+ (740.3281989999999)


   

PA(18:3(6Z,9Z,12Z)/5-iso PGF2VI)

PA(18:3(6Z,9Z,12Z)/5-iso PGF2VI)

C39H65O11P (740.426427)


   

PA(5-iso PGF2VI/18:3(6Z,9Z,12Z))

PA(5-iso PGF2VI/18:3(6Z,9Z,12Z))

C39H65O11P (740.426427)


   

PA(18:3(9Z,12Z,15Z)/5-iso PGF2VI)

PA(18:3(9Z,12Z,15Z)/5-iso PGF2VI)

C39H65O11P (740.426427)


   

PA(5-iso PGF2VI/18:3(9Z,12Z,15Z))

PA(5-iso PGF2VI/18:3(9Z,12Z,15Z))

C39H65O11P (740.426427)


   

PA(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C39H65O11P (740.426427)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z))

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z))

C39H65O11P (740.426427)


   

[1-amino-3-[(3S)-6,13-dimethyl-10-methylidene-2,5,9-trioxo-14-[(5E,7E)-3,7,10-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]-1-oxopropan-2-yl] hydrogen sulfate

[1-amino-3-[(3S)-6,13-dimethyl-10-methylidene-2,5,9-trioxo-14-[(5E,7E)-3,7,10-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]-1-oxopropan-2-yl] hydrogen sulfate

C36H60N4O10S (740.402994)


   
   
   

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C38H60O12S (740.380528)


   

[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C37H57O13P (740.3536601999999)


   

[1-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H57O13P (740.3536601999999)


   

Topostatin

Topostatin

C36H60N4O10S (740.402994)


A natural product found in Thermomonospora alba.

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2s,3r,4s,5s)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8's,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-8',16'-dioloxy]oxan-3-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5s)-2-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1'r,2r,2's,4's,5r,7's,8's,9's,12's,13'r,14'r,16'r)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-8',16'-dioloxy]oxan-3-yl]oxy}oxane-3,4,5-triol

C38H60O14 (740.398286)


   

5-[4,5-dimethoxy-2-({4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl}methyl)phenoxy]-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

5-[4,5-dimethoxy-2-({4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl}methyl)phenoxy]-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

C42H48N2O10 (740.3308788)


   

(9s)-5-(4,5-dimethoxy-2-{[(6s)-4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl]methyl}phenoxy)-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

(9s)-5-(4,5-dimethoxy-2-{[(6s)-4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl]methyl}phenoxy)-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

C42H48N2O10 (740.3308788)


   

5-[2,6-dimethoxy-3-({4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl}methyl)phenoxy]-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

5-[2,6-dimethoxy-3-({4-methoxy-7-methyl-2h,6h,8h,9h-[1,3]dioxolo[4,5-f]isoquinolin-6-yl}methyl)phenoxy]-4,14,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene

C42H48N2O10 (740.3308788)


   

1-[(3as,3bs,7r,9r,9ar,9bs,11as)-7-hydroxy-9-{[(2s,3r,4s,5s)-5-hydroxy-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(3as,3bs,7r,9r,9ar,9bs,11as)-7-hydroxy-9-{[(2s,3r,4s,5s)-5-hydroxy-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C37H56O15 (740.3619026)


   

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl formate

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl formate

C37H56O15 (740.3619026)